Cargando…

Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy

INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hastings, M. Colleen, Bursac, Zoran, Julian, Bruce A., Villa Baca, Emanuel, Featherston, Jennifer, Woodford, Susan Y., Bailey, Lisa, Wyatt, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762959/
https://www.ncbi.nlm.nih.gov/pubmed/29340319
http://dx.doi.org/10.1016/j.ekir.2017.08.008
_version_ 1783291799805100032
author Hastings, M. Colleen
Bursac, Zoran
Julian, Bruce A.
Villa Baca, Emanuel
Featherston, Jennifer
Woodford, Susan Y.
Bailey, Lisa
Wyatt, Robert J.
author_facet Hastings, M. Colleen
Bursac, Zoran
Julian, Bruce A.
Villa Baca, Emanuel
Featherston, Jennifer
Woodford, Susan Y.
Bailey, Lisa
Wyatt, Robert J.
author_sort Hastings, M. Colleen
collection PubMed
description INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a cohort of adults with IgA nephropathy with a long duration of follow-up. METHODS: Patient and kidney survival of 251 adult patients with IgA nephropathy from the southeastern United States diagnosed between January 1, 1976 and December 31, 2005 were analyzed. RESULTS: Median age at diagnosis was 36.9 years. Most patients were men (69%) and Caucasian (95%). Only 46% had an estimated glomerular filtration rate >60 ml/min per 1.73 m(2) at diagnosis. Mean follow-up time from time of diagnostic biopsy to death or end of study was 19.3 years. Of 251 patients, 132 (53%) progressed to ESRD and 97 (39%) died. Life expectancy was reduced by 10.1 years, with a median observed age of death at 65.7 years and a median expected age at death of 75.8 years. Eighty-three percent of the deaths occurred after progression to ESRD. CONCLUSION: Life expectancy is substantially reduced for patients diagnosed with IgA nephropathy in the southeastern United States.
format Online
Article
Text
id pubmed-5762959
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57629592018-01-16 Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy Hastings, M. Colleen Bursac, Zoran Julian, Bruce A. Villa Baca, Emanuel Featherston, Jennifer Woodford, Susan Y. Bailey, Lisa Wyatt, Robert J. Kidney Int Rep Clinical Research INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a cohort of adults with IgA nephropathy with a long duration of follow-up. METHODS: Patient and kidney survival of 251 adult patients with IgA nephropathy from the southeastern United States diagnosed between January 1, 1976 and December 31, 2005 were analyzed. RESULTS: Median age at diagnosis was 36.9 years. Most patients were men (69%) and Caucasian (95%). Only 46% had an estimated glomerular filtration rate >60 ml/min per 1.73 m(2) at diagnosis. Mean follow-up time from time of diagnostic biopsy to death or end of study was 19.3 years. Of 251 patients, 132 (53%) progressed to ESRD and 97 (39%) died. Life expectancy was reduced by 10.1 years, with a median observed age of death at 65.7 years and a median expected age at death of 75.8 years. Eighty-three percent of the deaths occurred after progression to ESRD. CONCLUSION: Life expectancy is substantially reduced for patients diagnosed with IgA nephropathy in the southeastern United States. Elsevier 2017-08-24 /pmc/articles/PMC5762959/ /pubmed/29340319 http://dx.doi.org/10.1016/j.ekir.2017.08.008 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Hastings, M. Colleen
Bursac, Zoran
Julian, Bruce A.
Villa Baca, Emanuel
Featherston, Jennifer
Woodford, Susan Y.
Bailey, Lisa
Wyatt, Robert J.
Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title_full Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title_fullStr Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title_full_unstemmed Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title_short Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
title_sort life expectancy for patients from the southeastern united states with iga nephropathy
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762959/
https://www.ncbi.nlm.nih.gov/pubmed/29340319
http://dx.doi.org/10.1016/j.ekir.2017.08.008
work_keys_str_mv AT hastingsmcolleen lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT bursaczoran lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT julianbrucea lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT villabacaemanuel lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT featherstonjennifer lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT woodfordsusany lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT baileylisa lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy
AT wyattrobertj lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy